 neither pre-licensure nor post-licensure. They admitted, for example, pre-licensed clinical trials have limited sample size and follow-up durations, and that there's not resources earmarked for post-authorization safety studies. This is an article, a paper they wrote. It is, there's one PhD, two PhDs, four or five doctors to this. Funding post-authorization vaccine safety science.